Clinical Trials Logo

Recurrent Prostate Cancer clinical trials

View clinical trials related to Recurrent Prostate Cancer.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT01913015 Terminated - Clinical trials for Adenocarcinoma of the Prostate

Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer

Start date: July 2013
Phase: Phase 1
Study type: Interventional

This randomized pilot phase I trial studies the side effects of dietary fat levels and abiraterone acetate uptake in patients with metastatic hormone-resistant prostate cancer. Abiraterone acetate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Eating a low or high fat diet may increase the uptake of abiraterone acetate.

NCT ID: NCT01866423 Terminated - Clinical trials for Adenocarcinoma of the Prostate

Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Start date: October 25, 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well orteronel works in treating patients with metastatic hormone-resistant prostate cancer. Orteronel may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01703065 Terminated - Clinical trials for Adenocarcinoma of the Prostate

Cabozantinib in Men With Castration-Resistant Prostate Cancer

Start date: June 18, 2013
Phase: Phase 2
Study type: Interventional

This pilot clinical trial studies cabozantinib in treating men with castration-resistant prostate cancer. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01469338 Terminated - Diarrhea Clinical Trials

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

Start date: July 2012
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well octreotide works in reducing diarrhea in patients receiving cabazitaxel and prednisone for hormone-resistant prostate cancer (HRPC) previously treated with docetaxel. Octreotide may prevent diarrhea by blocking the secretion of several hormones in patients receiving chemotherapy for prostate cancer

NCT ID: NCT01267266 Terminated - Clinical trials for Recurrent Prostate Cancer

Saracatinib in Treating Patients With Prostate Cancer

Start date: December 2010
Phase: Phase 2
Study type: Interventional

This randomized phase II clinical trial is studying how well saracatinib works in treating patients with prostate cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01200810 Terminated - Clinical trials for Adenocarcinoma of the Prostate

Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer

Start date: August 2010
Phase: Phase 2
Study type: Interventional

This partially randomized phase II trial is studying how well giving bicalutamide together with RO4929097 works in treating patients with previously treated prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body. RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving bicalutamide together with RO4929097 may be an effective treatment for prostate cancer

NCT ID: NCT01174199 Terminated - Prostate Cancer Clinical Trials

Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

Start date: February 2012
Phase: Phase 1
Study type: Interventional

RATIONALE: Temsirolimus and vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving temsirolimus together with vorinostat may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of temsirolimus and vorinostat in treating patients with metastatic prostate cancer.

NCT ID: NCT01126879 Terminated - Clinical trials for Adenocarcinoma of the Prostate

Genistein in Treating Patients With Prostate Cancer

Start date: February 3, 2011
Phase: Phase 2
Study type: Interventional

RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This randomized phase II trial is studying how well genistein works in treating patients with prostate cancer.

NCT ID: NCT01093183 Terminated - Clinical trials for Adenocarcinoma of the Prostate

Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer

Start date: March 4, 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of lenalidomide when given together with cyclophosphamide and to see how well they work in treating patients with previously treated hormone-refractory prostate cancer. Lenalidomide may stop the growth of prostate cancer by blocking blood flow to the tumor. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving lenalidomide together with cyclophosphamide may kill more tumor cells.

NCT ID: NCT00879619 Terminated - Prostate Cancer Clinical Trials

Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients

Start date: July 2009
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving docetaxel and prednisone together with sunitinib malate may kill more tumor cells. PURPOSE: This pilot phase I/II trial studies the side effects and best way to give docetaxel and prednisone together with sunitinib malate and to see how well it works in treating patients with prostate cancer that progressed after hormone therapy.